Northern Trust’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Northern Trust’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,746	Closed	-$10.2K	–	4604
2023 Q1	$10.2K	Hold	2,746	–	–	﹤0.01%	4523
2022 Q4	$10.4K	Hold	2,746	–	–	﹤0.01%	4567
2022 Q3	$22K	Hold	2,746	–	–	﹤0.01%	4532
2022 Q2	$58K	Hold	2,746	–	–	﹤0.01%	4369
2022 Q1	$103K	Hold	2,746	–	–	﹤0.01%	4329
2021 Q4	$154K	Hold	2,746	–	–	﹤0.01%	4290
2021 Q3	$198K	Hold	2,746	–	–	﹤0.01%	4186
2021 Q2	$263K	Sell	2,746 -6,368	-70%	-$703K	﹤0.01%	4025
2021 Q1	$1.35M	Sell	9,114 -798	-8%	-$145K	﹤0.01%	3455
2020 Q4	$1.39M	Buy	9,912 +175	+2%	+$28.4K	﹤0.01%	3372
2020 Q3	$1.48M	Buy	9,737 +37	+0.4%	+$6.04K	﹤0.01%	3206
2020 Q2	$1.7M	Buy	+9,700	New	+$1.62M	﹤0.01%	3119
2019 Q1	–	Sell	-339	Closed	-$11K	–	4268
2018 Q4	$11K	Sell	339 -9	-3%	-$652	﹤0.01%	4197
2018 Q3	$25K	Hold	348	–	–	﹤0.01%	4203
2018 Q2	$27K	Hold	348	–	–	﹤0.01%	4191
2018 Q1	$31K	Hold	348	–	–	﹤0.01%	4134
2017 Q4	$258K	Buy	348 +210	+152%	+$81.1K	﹤0.01%	3728
2017 Q3	$40K	Hold	138	–	–	﹤0.01%	4090
2017 Q2	$35K	Hold	138	–	–	﹤0.01%	4123
2017 Q1	$46K	Buy	138 +27	+24%	+$12.5K	﹤0.01%	4063
2016 Q4	$67K	Buy	111 +7	+7%	+$7.4K	﹤0.01%	3970
2016 Q3	$118K	Sell	104 -38	-27%	-$41K	﹤0.01%	3862
2016 Q2	$156K	Hold	142	–	–	﹤0.01%	3777
2016 Q1	$182K	Buy	142 +13	+10%	+$18.5K	﹤0.01%	3765
2015 Q4	$316K	Buy	129 +11	+9%	+$16.9K	﹤0.01%	3616
2015 Q3	$130K	Sell	118 -415	-78%	-$481K	﹤0.01%	3865
2015 Q2	$535K	Sell	533 -55	-9%	-$59.3K	﹤0.01%	3545
2015 Q1	$597K	Buy	588 +56	+11%	+$185K	﹤0.01%	3560
2014 Q4	$1.78M	Sell	532 -13	-2%	-$39.9K	﹤0.01%	3175
2014 Q3	$1.58M	Buy	545 +404	+287%	+$1.34M	﹤0.01%	3240
2014 Q2	$537K	Buy	141 +64	+83%	+$241K	﹤0.01%	3575
2014 Q1	$419K	Buy	+77	New	+$406K	﹤0.01%	3585

Other funds holding NBSE

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust's NBSE Position: Q2 2023 in Review

Northern Trust sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2023, closing a stake of 2,746 shares — an estimated $10.2K sold.

Northern Trust first reported a position in NBSE in Q1 2014 and held it in 32 quarters. The position peaked at $1.78M in Q4 2014. 27 funds tracked by Wall St. Rank hold NBSE as of Q2 2023.

Northern Trust reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Northern Trust sold 2,746 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $10.2K.
Northern Trust first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2014 and held it in 32 quarters.
Northern Trust's NeuBase Therapeutics, Inc. Common Stock position peaked at $1.78M in Q4 2014.
27 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Northern Trust's 13F filing for Q2 2023, filed 11 Aug 2023.